BETHESDA, MD 02 Jul 2013—Fresenius Kabi USA on June 30 announced a recall of four lots of benztropine mesylate injection vials bearing the company name "APP" or "Nexus Pharmaceuticals" on the label because the drug solution may contain glass particles.
The four lots are APP's 111412 and Nexus's 030712, 071212, and 090512.
APP Pharmaceuticals LLC is part of Fresenius Kabi USA. In May 2012, APP announced it had acquired benztropine mesylate injection and two other products from Nexus Pharmaceuticals Inc.
Fresenius said all the vials were manufactured by Allergy Laboratories Inc.
Customers are being told to return any unused vials from the four lots to Fresenius.
The company said it has stopped distributing benztropine mesylate vials while it investigates the cause of the problem with the product.